Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. - Test2 - elhamkhani - TriplyDB

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

http://www.wikidata.org/entity/Q35199072

about

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.The membrane as a target for controlling hypervirulent Clostridium difficile infections.Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes Clostridium difficile infection in the twenty-first century.Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.Fidaxomicin: a review of its use in patients with Clostridium difficile infection.Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.Antimicrobial activities of fidaxomicin Fidaxomicin inhibits spore production in Clostridium difficile.Role of fidaxomicin for the treatment of Clostridium difficile infection.In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.Fidaxomicin and OP-1118 inhibit C. difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-κB activity.Total Synthesis of Five Lipoteichoic acids of Clostridium difficile.Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay.

P2860

Q26770175-34AF9CF1-ABF8-4413-AAC6-554872210E2D Q34044442-02FD4AA5-1E43-4E80-960A-E295A28764A1 Q34331045-83143509-E74D-48BF-A419-B8C37BC4D674 Q35076880-DA921385-DADB-44AC-A069-ED0C87056203 Q36071501-77EFB2E9-0D79-4C4F-95D7-0F8C3666AA80 Q36963920-2ED2DF6C-7737-47B9-BDE5-48FA2AABDE45 Q36996876-8ED24C73-1C78-403D-8D62-FB472CA15AD6 Q37289567-74762184-208B-45F5-832E-C4199E4BE462 Q37933407-381F3A6D-4765-4E24-856C-BC1AA83767AF Q38153607-A98D2BD1-044A-4DD3-84AE-66F9262B5705 Q38719092-13BD0433-085D-46BA-903C-4C4EA7060D02 Q38848979-404F13C2-2C34-433A-BF26-45B2AF93EA25 Q39000863-AAF53048-89DB-4EAC-BC3B-25B600137FEE Q40065343-ECB62BAC-64F8-4BCA-A63A-0989D1D7E15B Q41148829-A0C61A99-F521-44F7-9B13-CA83A70C81D0 Q41233521-2D8C45FD-35F4-43F4-851C-B62BCABD677A Q41331732-CA7FEC91-3527-4DDB-8A5D-98CA15A3EF3D Q42222510-7D6261A1-7D39-4A55-B5D2-D7A4D92E2694 Q42222529-3DCA927A-8C7F-46DA-A6DE-FC91ACA878AC Q44579640-B497B14C-76D1-45B9-A2D1-98F4F86085E6 Q45730579-05B31268-8AA2-44E9-BE73-809499434418 Q46412261-0F29AC52-820A-4604-ABA2-4A1DBFB6AEB2 Q46846094-D7C8ECE4-D9E1-4938-92DF-31BE23E1140A Q55711857-11B39D96-69B9-4047-8C7F-20AAF847CBCB

P2860

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

http://www.wikidata.org/entity/Q35199072

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@ast

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@en

type

label

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@ast

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@en

prefLabel

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@ast

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@en

P1433

Q35199072-80353195-D046-425A-A112-D50B56727808

P1476

Q35199072-E9F29428-6F8E-42FA-893C-BBFC25AB7781

P2093

Q35199072-256B589D-57B2-4B74-B0ED-A6D941C0F37B

Q35199072-2728FEAA-0B2D-448B-8CCC-EC52193C3E3C

Q35199072-5B10918E-B7D8-447D-95B7-7DDF48D1DF56

Q35199072-E66181D9-9947-4B83-8D3C-890091DDA488

P2860

Q35199072-2CA41BDA-E03A-46C5-8B34-CDC122A13860

Q35199072-4C247745-6FF0-4428-92A6-58D8CC3D5163

Q35199072-6E513218-C313-4F43-ACCF-FA66E868B021

Q35199072-6FAFE8E5-4261-466F-80BD-B7C79638B4D2

Q35199072-8A5CA9A1-4822-4736-8820-19B55F0D1795

Q35199072-8A995ACF-B550-4B88-9397-5EA758BF1835

Q35199072-AFCCEC52-9A9F-4BFA-9D50-4BBEDCA155DE

Q35199072-B5FFEE8D-E5FA-4A25-AB16-9EA59B80EF00

Q35199072-B97A2B58-1FB8-49EB-8B8F-FBFD851D7015

Q35199072-D749E4E7-7C64-4699-A48E-334E4B2840B2

P304

Q35199072-F753E2BB-09B5-48D9-BECE-D1EDA7418458

P31

Q35199072-A3DAA939-FCBC-4AD7-B7D7-6B8C547232C6

P356

Q35199072-29133438-8B72-43E1-8DC9-2ACDC22470C7

P433

Q35199072-3C2D879A-31A9-46CF-8BDB-1ED9B245C6A0

P478

Q35199072-365F1096-67B2-4F60-B7F3-697E048F5313

P577

Q35199072-2714C11E-B615-4BA9-9BCB-A98DA05973A6

P5875

Q35199072-B1E57C5F-051E-4BD9-9352-4D2DAB772A77

P698

Q35199072-0506293D-8032-4115-99A8-8D0E61C95E98

P921

Q35199072-E96FBEDA-8FB8-4151-8F10-EC7CCF5AB593

P932

Q35199072-2EBF4FFD-17E3-46F7-9302-879D7E41CB39

P356

P1433

Journal of Medical Microbiology

P1476

Killing kinetics of fidaxomici ...... against Clostridium difficile.

@en

P2093

Abraham Gomez

http://www.w3.org/2001/XMLSchema#string

Farah Babakhani

http://www.w3.org/2001/XMLSchema#string

Nikki Robert

http://www.w3.org/2001/XMLSchema#string

Pamela Sears

http://www.w3.org/2001/XMLSchema#string

P2860

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

Clostridium difficile infection: new developments in epidemiology and pathogenesis

In vitro activity of OPT-80 against Clostridium difficile.

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Review of current literature on the economic burden of Clostridium difficile infection.

Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.

Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.

Initiation of transcription in vitro inhibited by lipiarmycin.

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

P304

1213-1217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1099/JMM.0.029470-0

http://www.w3.org/2001/XMLSchema#string

P433

Pt 8

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50196038

http://www.w3.org/2001/XMLSchema#string

P698

21349983

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

3167880

http://www.w3.org/2001/XMLSchema#string